Zura Bio ZURA 深 沪
等待开盘 01-24 09:30:00 美东时间
6.36
-0.090
-1.40%
华盛通- 最 高6.52
- 今 开6.46
- 成交量 52.80万股
- 最 低 6.1275
- 昨 收 6.45
- 总市值 4.14亿
- 52周最高 6.6302
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.97
- 委 比 -34.01%
- 总股本 6502.33万
- 历史最高 37.55
- 量 比 0.26
- 振 幅 6.09%
- 历史最低 0.97
- 每 手 1
- 风险率 1.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | NUAI飙升近25%，公司在德州合作开发大型数据中心；Lucid涨逾17%
NUAI飙升近25%，公司在德州合作开发大型数据中心；美国资源大涨24%，推出全球首个关键矿物实用代币；豪华电动车公司Lucid涨逾17%，沙特业务扩张势头迅猛>>
01-22 19:22
BUZZ-U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
BUZZ-U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks staged a modest recovery on Wednesday after the sharpest equities se
01-22 02:53
BUZZ-Zura Bio names new CEO; shares rise
BUZZ-Zura Bio names new CEO; shares rise ** Shares of drug developer Zura Bio ZURA.O rise 9.18% to $5.47 in early trading ** Co appoints Sandeep Kulkarni, a director on Zura's board, as CEO, replacing Robert Lisicki ** Kulkarni earlier co-founded Tourmaline Bio, later bought by Novartis NOVN.S ** O
01-21 23:38
Zura Bio Appoints Sandeep Kulkarni As CEO, Effective Immediately, Succeeding Kim Davis
Zura Bio Limited (Nasdaq: ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating
01-21 21:52
Zura Bio Names Sandeep Kulkarni CEO as Robert Lisicki Resigns
Zura Bio Names Sandeep Kulkarni CEO as Robert Lisicki Resigns Zura Bio Ltd. has appointed Sandeep Kulkarni, M.D. as Chief Executive Officer, effective January 21, 2026. Dr. Kulkarni will also continue as a Director of the company. He succeeds Kim Davis, J.D., who has served as Interim CEO since Octo
01-21 21:50
Zura Bio Updates Outlook and Clinical Development Plans
The latest announcement is out from Zura Bio ( ($ZURA) ). On January 12, 2026, ...
01-12 20:20
Zura Bio Targets Key 2026–2027 Trial Readouts as Lead Autoimmune Drug Advances, Eyes Transformational Data in 2026 as Tibulizumab Studies Progress
Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and
01-12 19:32
Zura Bio resets key agreements after internal review
An announcement from Zura Bio ( ($ZURA) ) is now available. On December 29, 202...
01-03 05:49
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock increased by 25.5% to $25.9...
2025-12-30 01:05
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points ...
2025-12-29 23:30
